285139-33-5

Upstream product

• 285139-32-4 N-[5-(N-4-toluenesulfonyl-amino)pyrimidin-4-yl]-L-4-(N,N-dimethylcarbarnyloxy)phenylalanine tert-butyl ester 
• 70-25-7 N-Methyl-N'-nitro-N-nitrosoguanidine 
• 77-78-1 dimethyl sulfate 
• 285139-36-8 N-(5-aminopyrimidin-4-yl)-L-4-(N,N-dimethylcarbamyloxy)phenylalanine tert-butyl ester 
• 285139-31-3 N-(2-chloro-5-nitropyrimidin-4-yl)-L-4-(N,N-dimethylcarbamyloxy)phenylalanine tert-butyl ester 
• 284486-57-3 L-4-(N,N-dimethylcarbamyloxy)phenylalanine tert-butyl ester 

Downstream Products

• 285139-34-6 N-[5-(N-methyl-N-4-toluenesulfonylamino)pyrimidin-4-yl]-L-4-(N,N-dimethylcarbarnyloxy)phenylalanine 

Relevant academic research and scientific papers

Arylsulfonamide pyrimidines as VLA-4 antagonists

A series of (S)-2-(2-(diethylamino)-5-(N-alkyl-N-sulfonamido)pyrimidin-4- ylamino)-3-(4-(carbamoyloxy)phenyl)propanoic acid is discovered as orally available VLA-4 antagonists. Representative compounds 11b and 11p showed efficacy in multiple in vivo anima

STEROID SPARING AGENTS AND METHODS OF USING SAME

This invention relates generally to the use of a steroid sparing agent for the preparation of a medicament for the treatment of inflammatory bowel diseases (IBD), asthma, multiple sclerosis (MS), rheumatoid arthritis (RA), graft versus host disease (GVHD), host versus graft disease, and various spondyloarthropathies, comprising administering a steroid sparing immunoglobulin or small molecule composition to a patient in need thereof. The invention also relates generally to combination therapies for the treatment of these conditions.